Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE versus HYDROGENATED ERGOT ALKALOIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE versus HYDROGENATED ERGOT ALKALOIDS.
HYDERGINE vs HYDROGENATED ERGOT ALKALOIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
Hydrogenated ergot alkaloids act as partial agonists/antagonists at α-adrenergic receptors, serotonergic (5-HT1B/1D) receptors, and dopaminergic receptors. They cause vasoconstriction by activating α-adrenoceptors and 5-HT receptors on vascular smooth muscle, and inhibit prolactin secretion via D2 receptor agonism.
1-2 mg orally three times daily.
1 mg orally three times daily, or 0.3 mg intramuscularly or subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
2-3 hours for dihydroergotamine; 12-15 hours for ergoloid mesylates, requiring cautious dosing in hepatic impairment.
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Primarily hepatic metabolism (70-80%) with biliary excretion; renal excretion accounts for less than 10% of unchanged drug.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid